-
Recent Posts
- Dementia-Friendly Communities Provision, Viewed as a Social Determinant of Health (JGCR / NHS England / WHO)
- International Perspectives on the Possible Impact of the COVID-19 Pandemic and Lockdown on Abuse of the Elderly (JGCR / American Journal of Geriatric Psychiatry / JAGS)
- Updates Relating to the Lancet Commission on Dementia Prevention, Intervention, and Care (Lancet / Alzheimer’s Research and Therapy / Alzheimer’s and Dementia)
- A Brief Review of How the COVID-19 Pandemic Relates to Elderly Care and Research (JGCR)
- Some Speculated / Potential Benefits of COVID-19 (JGCR / BBC Radio 4’s Rethink / BGS)
Archives
- September 2020
- August 2020
- June 2020
- April 2020
- March 2020
- February 2020
- January 2020
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Cognitive Impairment in Parkinson’s Disease
Cognitive Impairment in Parkinson’s Disease: the State of Current Understanding (NPJ Parkinson’s Disease)
Summary The following review summarises a recent conference on the topic of cognitive impairment encountered in Parkinson’s Disease. Full Text Link Reference Goldman, JG. Vernaleo, BA. [and] Camicioli, R. [et al] (2018). Cognitive impairment in Parkinson’s disease: a report from … Continue reading →
Posted in Acute Hospitals, Charitable Bodies, Community Care, Diagnosis, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), Integrated Care, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Parkinson's Disease, Person-Centred Care, Quick Insights, Statistics, Universal Interest
|
Tagged Barrow Neurological Institute (Phoenix), Boston University, Boston University Medical Campus, Canada, Center for Neuromodulation: Barrow Neurological Institute, Center for Neurorehabilitation: Boston University, Charles E. Schmidt College of Medicine: Florida Atlantic University, Cognitive Decline, Cognitive Impairment, Cognitive Impairment in Parkinson's Disease, College of Health Sciences: Rush University Medical Center, Department of Clinical and Health Psychology: University of Florida, Department of Clinical Neuropsychology: Barrow Neurological Institute, Department of Clinical Nutrition: Rush University Medical Center, Department of Health and Aging: Rush University Medical Center, Department of Medicine: University of Alberta, Department of Medicine: University of Pennsylvania, Department of Neurological Sciences: Rush University Medical Center, Department of Neurology: Boston University Medical Campus, Department of Neurology: University of Iowa, Department of Neurology: University of Maryland School of Medicine, Department of Neurology: University of Miami, Department of Neurology: University of Pennsylvania, Department of Physical Therapy and Athletic Training: Boston University, Department of Psychiatry and Psychology: Mayo Clinic (Rochester), Department of Psychiatry: Rutgers The State University of New Jersey, Division of Neuropsychology: University of Miami, Edmond J Safra Program in Parkinson’s Disease: Toronto Western Hospital, Florida Atlantic University, Lewy Body Parkinson Disease, MCI: Mild Cognitive Impairment, Mediterranean-DASH Intervention for Neurodegenerative Delay: MIND, Memory Controllability Inventory (MCI), Mild Cognitive Impairment in Parkinson's Disease (MCI-PD), Morton and Gloria Shulman Movement Disorders Centre: Toronto Western Hospital, Movement Disorder Society (MDS) Task Forces for PDD and PD-MCI Diagnostic Criteria, Neurology Service: Iowa City, NPJ Parkinson’s Disease, Parkinson's Disease Foundation Community Choice Research Award Program, Parkinson's Foundation, Parkinson’s Dementia, Parkinson’s Disease Dementia, PD Cognitive Impairment, Pre-Dementia (MCI), Risk of Cognitive Impairment and Dementia, Rush University Medical Center, Rutgers The State University of New Jersey, Section of Parkinson Disease and Movement Disorders: Rush University Medical Center, Toronto Western Hospital, United States, University Health Network: University of Toronto, University of Alberta, University of Florida, University of Iowa, University of Maryland School of Medicine, University of Miami, University of Pennsylvania, University of South Florida, University of Toronto, Unmet Needs, USA, Veterans Affairs Health Care System (Iowa City)
|
Leave a comment
Issues in the Clinical Diagnosis of Dementia with Lewy Bodies (Translational Neurodegeneration)
Summary This article discusses recent progress, and problems remaining, in the clinical diagnosis of Dementia with Lewy Bodies (DLB). The sensitivity of accurate clinical diagnosis of DLB is said to be low. It seems likely that it may be possible … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Researchers (mostly), International, Universal Interest
|
Tagged (123)I-FP-CIT: (123)I-2beta-carbometoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl) nortropane, Aβ Deposition in DLB, Amyloid Beta Protein, Antipsychotics: Neuroleptic Sensitivity, Assessment of Fluctuation Scales, Australia, Beta-Amyloid, Beta-Amyloid Plaques, CIND-PD: Cognitive Impairment in Parkinson's Disease, Cognitive Impairment in Parkinson's Disease, Cognitive Impairment in Parkinson's Disease (CIND-PD), DaTSCAN, Delusional Ideas, Delusions, Dementia in Parkinson's Disease, Dementia with Lewy Bodies, Dementia With Lewy Bodies (DLB), Dementia with Lewy Bodies Symptoms, Dementia with Lewy Bodies Translational Neurodegeneration, Diagnosis and Management of Dementias of Lewy Body Type in the NHS (DIAMAND-Lewy), Diagnosis and Screening: Dementia with Lewy Bodies, Differential Diagnosis, DLB: Dementia with Lewy Bodies, Dopamine, Dopamine Denervation, Early Differential Diagnosis, Fluctuating Cognition, Fluctuation Assessment Scales, Frederick Lewy, Genetics of DLB, Glucocerebrosidase Gene Mutations, Hallucinations, Hallucinations in People with Dementia, I-123 MIBG: Iodine-123 Metaiodobenzilguanidine, α-Synuclein, β-amyloid, β-amyloid Deposition, β-Amyloid Oligomerization, β-Synuclein, γ-Synuclein, Lewy Body Degeneration, Lewy Body Dementia, Lewy-Related Pathologies (LRP), Low Dopamine Transporter Uptake, LRP: Lewy-Related Pathology, Neuroleptic Sensitivity, Neuroscience Research Australia, Parkinson’s Disease Dementia, PDD: Parkinson's Disease with Dementia, Severe Neuroleptic Sensitivity, SPECT, Sydney, University of New South Wales, Visual Hallucinations
|
Leave a comment
Recent Systematic Reviews on Parkinson’s Disease (October – December 2012)
[A version of this collection appeared in Dementia and Elderly Care: the Latest Evidence Newsletter (RWNHST), Volume 3 Issue 5, January 2013]. Recent systematic reviews and meta-analyses concerning Parkinson’s Disease are shown below. Pan, PL. Shi, HC. Zhong, JG. [et al]. … Continue reading →
Posted in For Doctors (mostly), For Researchers (mostly), International, Parkinson's Disease, Systematic Reviews
|
Tagged Atrophy and Cognition, Cognitive Impairment in Parkinson's Disease, Driving, Grey-Matter Volume, Parkinson’s Disease Dementia, Parkinsonian Symptoms, Parkinsonism, Selected Systematic Reviews and Meta-Analyses
|
Leave a comment
Parkinson’s Disease Public Awareness Campaign (Parkinson’s UK, formerly the Parkinson’s Disease Society)
Summary Parkinson’s UK launched their first public awareness campaign earlier this month. The aim is to raise knowledge of the condition and improve understanding of the impact that Parkinson’s Disease has on sufferers. “Parkinson’s can affect messages the brain gives to … Continue reading →
Posted in Charitable Bodies, For Carers (mostly), For Nurses and Therapists (mostly), National, Parkinson's Disease, Quick Insights, UK, Universal Interest
|
Tagged Awareness, Awareness Raising, Campaigning, Cognitive Impairment in Parkinson's Disease, Dementia in Parkinson's Disease, Parkinson's Disease Public Awareness Campaign, Parkinson’s UK, Public Awareness (Parkinson's Disease)
|
Leave a comment
Cholinesterase Inhibitors for Dementia with Lewy Bodies, Parkinson’s Disease Dementia and Cognitive Impairment in Parkinson’s Disease (Cochrane Library)
[A version of this item appears in: Dementia: the Latest Evidence Newsletter (RWHT), Volume 2 Issue 9, April 2012]. Summary Earlier Cochrane reviews have examined the use of cholinesterase inhibitors in both Parkinson’s Disease with dementia (PDD) and dementia with … Continue reading →
Posted in Acute Hospitals, Community Care, For Doctors (mostly), For Researchers (mostly), Pharmacological Treatments, Systematic Reviews, Universal Interest
|
Tagged Acetylcholine, ADCS (Scale), ALOIS: the Cochrane Dementia and Cognitive Improvement Group, Behavioural Disturbance Rating Scales, Cholinesterase Inhibitors, CIND-PD: Cognitive Impairment in Parkinson's Disease, Cognitive Impairment in Parkinson's Disease, Cognitive Impairment in Parkinson's Disease (CIND-PD), Dementia with Lewy Bodies, DLB: Dementia with Lewy Bodies, Donepezil, Donepezil (Aricept), John Radcliffe Hospital, Mini Mental State Examination (MMSE), Oxford University Hospitals NHS Trust, Parkinson’s Disease Dementia, Parkinsonian Symptoms, PDD: Parkinson's Disease with Dementia, Rivastigmine, Unified Parkinson's Disease Rating Scale (UPDRS)
|
Leave a comment
